{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ankylosing-spondylitis/management/suspected-ankylosing-spondylitis/","result":{"pageContext":{"chapter":{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis","depth":2,"htmlHeader":"<!-- begin field 69edcac5-03fb-47ac-86c0-057bdbdb7931 --><h2>Scenario: Suspected ankylosing spondylitis</h2><!-- end field 69edcac5-03fb-47ac-86c0-057bdbdb7931 -->","summary":"Covers the initial management of suspected ankylosing spondylitis in primary care, when to refer, and what advice to give.","htmlStringContent":"<!-- begin item 9e907463-9e39-45c5-8b0d-6ad67d788166 --><!-- begin field 0f4c2ada-c1e8-41e4-b93d-acbd0086dfd3 --><p>From age 16 years onwards.</p><!-- end field 0f4c2ada-c1e8-41e4-b93d-acbd0086dfd3 --><!-- end item 9e907463-9e39-45c5-8b0d-6ad67d788166 -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","lastRevised":"Last revised in May 2019","chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5f990a53-f20c-5891-a8a8-e3180df6954d","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 374a83d8-827d-4f47-8853-b0840361eec4 --><h3>What advice should I give a person with suspected ankylosing spondylitis?</h3><!-- end field 374a83d8-827d-4f47-8853-b0840361eec4 -->","summary":null,"htmlStringContent":"<!-- begin item 1382f911-e954-44f7-b76f-bff8bb7a0a19 --><!-- begin field 55cd023b-b35c-475a-8a82-b9c5ab5f725c --><ul><li><strong>Advise that d</strong><strong>iagnosis of ankylosing spondylitis can be difficult and referral to a rheumatologist is required for confirmation.</strong><ul><li>Clinical features and diagnostic tests for ankylosing spondylitis can help make the diagnosis, but no symptom, sign, or test result in isolation is useful for diagnosis. The rheumatologist may arrange blood tests and x-rays (and MRI if there are no x-ray changes). For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/diagnosis/investigations/\">Investigations</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/diagnosis/\">Diagnosis</a>. </li></ul></li></ul><!-- end field 55cd023b-b35c-475a-8a82-b9c5ab5f725c --><!-- end item 1382f911-e954-44f7-b76f-bff8bb7a0a19 -->","subChapters":[{"id":"db490490-2a62-5885-a12e-d373150cbbaa","slug":"basis-for-recommendation-f3d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3042314a-7bde-4c44-a70c-f957cef9a5fb --><h4>Basis for recommendation</h4><!-- end field 3042314a-7bde-4c44-a70c-f957cef9a5fb -->","summary":null,"htmlStringContent":"<!-- begin item f3da7bdb-05c3-4c27-852c-2350c1d49451 --><!-- begin field a66789b6-5d67-4701-b8bf-ee5379c51ba0 --><h5>Advice for people with suspected ankylosing spondylitis</h5><p>This recommendation is based on the National Institute for Health and Care Excellence guideline <em>Spondyloarthritis in over 16s: diagnosis and managment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].</p><ul><li>Axial spondyloarthritis is difficult to diagnose without specialist assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2018</a>] and should not be ruled out solely on the presence or absence of any individual sign, symptom, or test result [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]. </li></ul><!-- end field a66789b6-5d67-4701-b8bf-ee5379c51ba0 --><!-- end item f3da7bdb-05c3-4c27-852c-2350c1d49451 -->","subChapters":[]}]},{"id":"35ecdca6-7a3c-5a46-a433-61b015936835","slug":"initial-treatment","fullItemName":"Initial treatment","depth":3,"htmlHeader":"<!-- begin field 2407b2f7-d1fb-4bc5-97c3-9d2c98f26e12 --><h3>What treatment should I start for someone with suspected ankylosing spondylitis while waiting for referral?</h3><!-- end field 2407b2f7-d1fb-4bc5-97c3-9d2c98f26e12 -->","summary":null,"htmlStringContent":"<!-- begin item 3d8d45e7-90e7-4e57-b616-6260512e4787 --><!-- begin field 0639d11f-e383-4258-8f23-619f458353bf --><ul><li><strong>Consider prescribing a nonsteroidal anti-inflammatory drug (NSAID) </strong>while waiting for referral. Take account of the person's risk of serious adverse effects, the safety profiles of individual standard NSAIDs or coxibs, the person's ability to tolerate individual NSAIDs, their other medications, and their preferences. <ul><li>To minimise the risks of long-term NSAIDs, use the lowest effective dose.</li><li>Monitor risk factors and consider the use of gastroprotective treatment.<ul><li>If the person is at increased risk of cardiovascular, renal, or gastrointestinal (GI) adverse effects, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for more information on prescribing NSAIDs, including gastroprotection.</li></ul></li><li>If an NSAID taken at the maximum tolerated dose for 2–4 weeks does not provide adequate pain relief, consider switching to another NSAID.<strong> </strong></li></ul></li><li><strong>If NSAIDs are contraindicated, consider prescribing a standard analgesic </strong>(for example paracetamol with or without codeine). Note that non-NSAID analgesics will not control inflammation.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul></li></ul><!-- end field 0639d11f-e383-4258-8f23-619f458353bf --><!-- end item 3d8d45e7-90e7-4e57-b616-6260512e4787 -->","subChapters":[{"id":"23ce413b-3db0-5731-8401-fc029d277fef","slug":"basis-for-recommendation-272","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 40659ab5-fbdd-4377-b80c-2a68b4359774 --><h4>Basis for recommendation</h4><!-- end field 40659ab5-fbdd-4377-b80c-2a68b4359774 -->","summary":null,"htmlStringContent":"<!-- begin item 272cadd4-9f3c-4cad-8ad7-7c5c92dca5e0 --><!-- begin field 319e0aab-b16f-4d2a-b731-a3910628c51f --><h5><strong>Nonsteroidal anti-inflammatory drugs </strong><strong>(NSAIDs)</strong></h5><ul><li>This recommendation is consistent with the National Institute for Health and Care Excellence (NICE) guideline <em>Spondyloarthritis in over 16s: diagnosis and managment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]<strong> </strong>and also reflects ASAS-EULAR recommendations for axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>], and advice from the American College of Rheumatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>], and the Canadian Rheumatology Association [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]. NSAIDs can be initiated in primary care before confirmation of the diagnosis of spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">McAllister et al, 2017</a>]. <ul><li>NSAIDs are particularly useful in people with axial spondyloarthritis, with benefit seen in terms of pain reduction with most NSAIDs. There is debate as to whether NSAIDs modify radiological progression in axial inflammation when a person has raised inflammatory markers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].<strong> </strong></li></ul></li><li>A Cochrane systematic review (search date June 2014) found 39 studies (n = 4356) on NSAID use in people with axial spondyloarthritis, although no trials included in the meta-analyses assessed people with non-radiographic axial spondyloarthritis. The findings were [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kroon et al, 2015</a>]: <ul><li>Better pain relief with NSAIDs compared with placebo with a 16.5 points lower visual analogue score in the NSAID group (high quality evidence, n = 850, 95% CI –20.8 to –12.2, number needed to treat [NNT] = 4).</li><li>Improved disease activity with NSAIDs compared with placebo (moderate quality evidence, n = 190, 17.5 points lower disease activity index score in the NSAID group, 95% CI –23.1 to –11.8, NNT = 3).</li><li>Improved function with NSAIDs compared with placebo (high quality evidence, n = 356, 9.1 points lower functional index score in the NSAID group, 95% CI –13.0 to –5.1, NNT = 5).</li><li>No significant difference in adverse effects between the NSAID and placebo groups after 12 weeks (moderate and low quality evidence).</li><li>Equal effectiveness between NSAID classes in terms of benefits or harms.</li></ul></li><li>NICE and the American College of Rheumatology do not recommend a preferred NSAID [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>] and there is no clear difference in the effectiveness of NSAIDs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper and Poddubnyy, 2017</a>]. </li><li>The NICE guideline development group noted that comorbidities influence the choice of NSAID [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. Cardiovascular, gastrointestinal, and renal risks of NSAIDs should be considered when prescribing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kroon et al, 2015</a>]. </li></ul><h5>Paracetamol and other analgesics</h5><ul><li>This recommendation is based on the ASAS-EULAR and Canadian management recommendations for spondyloarthritis which, despite a lack of formal evidence, suggest analgesics (for example paracetamol and opioid-[like] drugs) might be considered for residual pain if other recommended treatments are contraindicated, poorly tolerated, or have failed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li></ul><!-- end field 319e0aab-b16f-4d2a-b731-a3910628c51f --><!-- end item 272cadd4-9f3c-4cad-8ad7-7c5c92dca5e0 -->","subChapters":[]}]},{"id":"153566aa-1133-5244-a53e-5a1542781565","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field f34fc168-1426-471c-8c4f-04352012a249 --><h3>When should I refer a person with suspected ankylosing spondylitis?</h3><!-- end field f34fc168-1426-471c-8c4f-04352012a249 -->","summary":null,"htmlStringContent":"<!-- begin item e5b02ebe-1dd9-4962-93c2-16b772e9916c --><!-- begin field 9175307f-3eb5-4799-909a-b8b931d73d2c --><ul><li><strong>Refer to rheumatology for a spondyloarthritis assessment</strong> if a person has low back pain starting before the age of 45 years and lasting longer than 3 months, plus four or more of the following criteria:<ul><li>Low back pain starting before the age of 35 years.</li><li>Symptoms which wake them during the second half of the night.</li><li>Buttock pain.</li><li>Improvement when moving.</li><li>Improvement within 48 hours of taking a nonsteroidal anti-inflammatory drug (NSAID).</li><li>Spondyloarthritis in a first-degree relative.</li><li>Current or past arthritis.</li><li>Current or past enthesitis.</li><li>Current or past psoriasis.</li></ul></li><li>If exactly 3 of the additional criteria are present, perform an HLA-B27 test. If the test is positive, refer the person to a rheumatologist for a spondyloarthritis assessment.</li><li>If axial spondyloarthritis is <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/diagnosis/diagnosis/\">suspected</a>, but the person does not meet the criteria for referral, advise them to return for further assessment if they develop new signs, symptoms, or risk factors (particularly if there is a history of current or past inflammatory bowel disease, psoriasis, or uveitis).</li><li><strong>Refer urgently (same day) to ophthalmology </strong>if anterior uveitis (iritis) is suspected.<ul><li>Suspect acute anterior uveitis when an eye becomes red and acutely painful especially if there is also photophobia or blurred vision.</li></ul></li></ul><!-- end field 9175307f-3eb5-4799-909a-b8b931d73d2c --><!-- end item e5b02ebe-1dd9-4962-93c2-16b772e9916c -->","subChapters":[{"id":"d79d54c9-c727-51f9-8c29-53fbb6e1ef5c","slug":"basis-for-recommendation-b8c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7f308a5a-e631-4750-9fe9-03442ad52508 --><h4>Basis for recommendation</h4><!-- end field 7f308a5a-e631-4750-9fe9-03442ad52508 -->","summary":null,"htmlStringContent":"<!-- begin item b8cee023-40b1-4d70-92e5-b860f829a506 --><!-- begin field f7e734a6-794a-4492-831f-48abb48ed2aa --><p>This recommendation reflects the National Institute for Health and Care Excellence (NICE) guidance <em>Spondyloarthritis in over 16s: diagnosis and management </em>which outlines criteria for referral to a rheumatologist for a spondyloarthritis assessment based on symptoms and previous and family history [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>].</p><ul><li>The NICE guideline development group noted that individual signs, symptoms, and risk factors alone may not be sufficient to warrant referral or make an accurate diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. Prompt diagnosis is important as delays in confirming spondyloarthritis can cause significant morbidity. Specialist referral can reduce the delay in diagnosis and improve access to appropriate treatment and outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2018</a>].</li><li>Axial spondyloarthritis is difficult to diagnose without specialist assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2018</a>]<strong> </strong>and experts agree that axial spondyloarthritis is usually diagnosed and its management coordinated by rheumatologists as it requires multidisciplinary management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li><li>Referral to rheumatology of suspected cases of ankylosing spondylitis will allow the rheumatologist to [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]: <ul><li>Confirm the diagnosis.</li><li>Review current treatment including any need for biological DMARDs.</li><li>Refer to physiotherapy for an individualised, structured exercise programme, including stretching, strengthening and postural exercises and range of motion exercises for the lumbar, thoracic, and cervical spine.</li><li>Refer to a specialist therapist (for example occupational therapy or physiotherapy) if the person has difficulty with activities of daily living for an assessment and advice on physical aids.</li><li>Arrange regular osteoporosis assessments (every 2 years).</li><li>Make arrangements for follow up and monitoring, which may be a shared care arrangement.</li></ul></li><li>The NICE guideline development group also acknowledged the need for urgent ophthalmological assessment of people presenting with anterior uveitis in order to prevent potential sight damage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].</li></ul><!-- end field f7e734a6-794a-4492-831f-48abb48ed2aa --><!-- end item b8cee023-40b1-4d70-92e5-b860f829a506 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}